INTRODUCTION {#s1}
============

Cancer is reportedly one of the major causes of death among human worldwide \[[@R1]\]. According to GLOBOCAN 2012 report, there were 14.1 million new cases and 8.2 million deaths in 2012 \[[@R2]\]. Recently reported, as a very complex genetic disease, the mechanism of cancer has not been completely elucidated. Moreover, studies have suggested that cancer development results from gene-environment interactions \[[@R3]\].

MicroRNAs (miRNAs) are a class of endogenous small single-stranded, long non-coding RNA molecules, which play critical roles in a extensive range of biologic and pathologic processes, especially in carcinogenesis \[[@R4]--[@R5]\]. Accumulating studies indicates that a single miRNA cantarget 200 genes, and approximately 20% of human genes are regulated by the mature miRNA molecules \[[@R6]\]. More than half of miRNAs genes are located in cancer-related genomic regions, indicating that these miRNAs may play a more important key role in the etiology, tumorigenesis, development and prognosis of human cancers than previous research \[[@R7]\].

Single nucleotide polymorphisms (SNPs) occurring in the miRNA gene region may influence the function of specific miRNA molecules and the genetic variation, which are associated with cancer susceptibility through altering miRNA molecules expression \[[@R8]--[@R9]\]. Recently, miR-196a2C.T (rs11614913) and miR-499 A.G (rs3746444) have been reported to demonstrate the association with malignant tumors susceptibility \[[@R10]--[@R17]\]. For instance, Min et al. \[[@R11]\] demonstrates that the miRNA variants could affect the development of colorectal cancer in the Korean, while Georgeh et al. \[[@R17]\]. showed miR-196a2C.T (rs11614913)and miR-499 A.G (rs3746444) revealed significant risk for developing prostate cancer in North Indian. However, the consequences of these relevant studies remain incomprehensive and controversial. To the best of our knowledge, there is no systematic and comprehensive reports or studies regarding the impact of miR196a2 and miR-499 variants on overall cancer risk in world wide population. Hence, we performed a meta-analysis to clarify the associaton between the miR-196a2C.T (rs11614913)and miR-499 A.G (rs3746444) polymorphisms with cancer susceptibility.

MATERIALS AND METHODS {#s2}
=====================

Publication search {#s2_1}
------------------

We carried out a search in PubMed, ISI Web of Knowledge, EMBASE, Chinese National Knowledge Infrastructure(CNKI) databases for all relevant reports using the key words "microRNA 192" OR "microRNA-192" OR "miR-192" OR "rs11614913" OR "microRNA 499" OR "microRNA-499" OR "miR-499" OR " rs3746444") AND ("polymorphism" OR "SNP" OR "variation" OR "locus" OR "mutation") AND ("cancer" OR "tumor" OR "malignancy" OR "carcinoma" OR "neoplasm"(updated to Dec 30, 2016). The search was limited to English language papers and human subject studies. We evaluated potentially relevant publications by examining their titles and abstracts, thereafter all studies matching the eligible inclusion criteria were retrieved.

Selection criteria {#s2_2}
------------------

The following criteria were used to select studies for further meta-analysis: (a) about the miR-196a2 rs11614913/miR-499 rs3746444 polymorphisms and cancer risk, (b) full-text study, (c) from a case-control designed study, (d) genotype frequencies available, (e) sufficient published data for estimating an odds ratio (OR) with 95% confidence interval (CI).

Accordingly, the following exclusion criteria were also used: (a) the design of the experiments were not case-control studies; (b) the source of cases and controls, and other essential information were not provided; (c) reviews and duplicated publications.

Data extraction {#s2_3}
---------------

All data were independently abstracted in duplicate by two investigators (Yan and Zhang) using a standard protocol and data-collection form according to the inclusion criteria listed above. The following information was sought from each publication: the first author's name, year of publication, country of origin, ethnicity, cancer type, source of control (population- or hospital-based controls), genotyping method and number of cases and controls miR-196a2 C/T and/or miR-499 G/A genotypes, respectively (Table [1](#T1){ref-type="table"}). Different ethnicity descents were categorized as Caucasian and Asian.

###### Summary of published studies included

  ---------------------------------------------------------------------------------------------------------------------------------------------
       Author                    Year   Race        Cancer type                    Control   Method      Case/control   Polymorphism site
  ---- ------------------------- ------ ----------- ------------------------------ --------- ----------- -------------- -----------------------
  1    Ahn \[[@R22]\]            2012   Asian       gastric cancer                 PB        PCR--RFLP   461/477        rs11614913, rs3746444

  2    Alshatwi \[[@R23]\]       2012   Asian       Breast Cancer                  PB        PCR--RFLP   89/100         rs11614913, rs3746444

  3    B.Zhou \[[@R24]\]         2011   Asian       Cervical Squamous\             PB        PCR--RFLP   226/309        rs11614913, rs3746444
                                                    Cell Carcinoma                                                      

  4    Bansal \[[@R25]\]         2014   Asian       breast cancer                  PB        PCR--RFLP   121/164        rs11614913, rs3746444

  5    Behnaz \[[@R26]\]         2016   Caucasian   HCC                            PB        PCR         103/432        rs11614913

  6    Brajušković \[[@R27]\]    2015   Caucasian   prostate cancer                PB        PCR--RFLP   355/312        rs11614913, rs3746444

  7    Catucci \[[@R28]\]        2012   Caucasian   breast cancer                  PB        PCR--RFLP   1894/2760      rs11614913, rs3746444

  8    cheng \[[@R29]\]          2015   Asian       gastric cancer                 HB        MassARRAY   363/969        rs3746444

  9    Chu \[[@R30]\]            2012   Asian       Oral Cancer                    PB        PCR--RFLP   470/425        rs11614913, rs3746444

  10   D. Li \[[@R31]\]          2015   Asian       HCC                            PB        RT-PCR      184/184        rs3746444

  11   Dai \[[@R32]\]            2016   Asian       breast cancer                  HB        MassARRAY   560/583        rs11614913, rs3746444

  12   Deng \[[@R33]\]           2015   Asian       bladder cancer                 PB        PCR--RFLP   159/298        rs11614913, rs3746444

  13   Dominik \[[@R34]\]        2011   Caucasian   Breast Cancer                  PB        PCR--RFLP   187/171        rs11614913

  14   Dou \[[@R35]\]            2010   Asian       glioma                         PB        PCR--RFLP   643/656        rs11614913

  15   Eman \[[@R36]\]           2016   Caucasian   Hepatic/Renal Cancer           PB        RT-PCR      65/150         rs11614913, rs3746444

  16   Gu \[[@R37]\]             2013   Asian       esophageal cancer              PB        PCR--RFLP   380/380        rs11614913, rs3746444

  17   H. Chen \[[@R38]\]        2011   Asian       colorectal cancer              HB        PCR--LDR    126/407        rs11614913

  18   H. Zhao \[[@R39]\]        2016   Asian       breast cancer                  HB        RT-PCR      114/114        rs11614913

  19   Hashemi \[[@R40]\]        2016   Asian       prostate cancer                PB        PCR--RFLP   169/182        rs11614913, rs3746444

  20   Hikmet \[[@R41]\]         2011   Caucasian   HCC                            PB        PCR--RFLP   222/222        rs3746444

  21   Hong \[[@R42]\]           2011   Asian       Lung Cancer                    HB        PCR--RFLP   406/428        rs11614913

  22   Hu \[[@R43]\]             2013   Asian       Glioma                         HB        PCR--RFLP   680/690        rs11614913, rs3746444

  23   J. Shi \[[@R44]\]         2015   Asian       gastric cancer                 PB        RT-PCR      448/452        rs3746444

  24   Kim \[[@R45]\]            2012   Asian       colorectal cancer              PB        PCR--RFLP   201/159        rs11614913, rs3746444

  25   Kim \[[@R46]\]            2011   Asian       lung cancer                    PB        PCR--RFLP   654/640        rs11614913

  26   Kou \[[@R47]\]            2014   Asian       HCC                            PB        PCR--RFLP   271/532        rs11614913, rs3746444

  27   Kshitij \[[@R48]\]        2010   Asian       gallbladder cancer             PB        PCR--RFLP   230/230        rs11614913, rs3746444

  28   Kuo \[[@R49]\]            2014   Asian       HCC                            PB        PCR--RFLP   188/377        rs11614913, rs3746444

  29   Li \[[@R50]\]             2015   Asian       non-Hodgkin lymphoma           PB        RT-PCR      318/320        rs11614913

  30   Linhare \[[@R51]\]        2012   Caucasian   Breast cancer                  PB        TaqMan      388/388        rs11614913

  31   LIU \[[@R52]\]            2010   Asian       HCC                            HB        PCR--RFLP   310/222        rs11614913

  32   Lv \[[@R53]\]             2013   Asian       colorectal cancer              PB        PCR--RFLP   353/540        rs11614913

  33   M. Zhang \[[@R54]\]       2012   Asian       Breast Cancer                  PB        PCR--RFLP   252/248        rs11614913

  34   Masaaki \[[@R55]\]        2010   Asian       gastric cancer                 PB        PCR--RFLP   552/697        rs11614913, rs3746444

  35   Min \[[@R11]\]            2012   Asian       Colorectal Cancer              PB        PCR--RFLP   446/502        rs11614913, rs3746444

  36   Morales \[[@R56]\]        2016   Caucasian   Breast cancer                  PB        TaqMan      440/807        rs11614913

  37   N. Wang \[[@R57]\]        2014   Asian       ESCC                           PB        PCR-LDR     597/597        rs11614913

  38   Ni \[[@R58]\]             2015   Asian       endometrial/ovarian cancer     PB        PCR         141/100        rs11614913, rs3746444

  39   Omrani \[[@R59]\]         2014   Asian       breast cancer                  PB        PCR         236/203        rs11614913, rs3746444

  40   P. Dikaiakos \[[@R60]\]   2015   Caucasian   colorectal cancer              PB        PCR--RFLP   157/299        rs11614913

  41   P. Li \[[@R61]\]          2014   Asian       Nasopharyngeal Carcinoma       PB        RT-PCR      1020/1006      rs11614913

  42   P. Qi \[[@R62]\]          2015   Asian       breast cancer                  PB        PCR--RFLP   321/290        rs11614913, rs3746444

  43   Panagiotis \[[@R63]\]     2014   Caucasian   gastric cancer                 HB        PCR--RFLP   163/480        rs11614913

  44   Pavlakis \[[@R64]\]       2013   Caucasian   pancreatic cancer              HB        PCR--RFLP   93/122         rs11614913

  45   Peng \[[@R65]\]           2010   Asian       gastric cancer                 HB        PCR--RFLP   231/213        rs11614913

  46   Qi \[[@R66]\]             2011   Asian       HCC                            PB        PCR--LDR    361/391        rs11614913

  47   Qu \[[@R67]\]             2014   Asian       ESCC                           HB        PCR--RFLP   381/426        rs11614913

  48   Rama \[[@R68]\]           2010   Asian       Bladder Cancer                 PB        PCR--RFLP   212/250        rs11614913, rs3746444

  49   Renata \[[@R69]\]         2012   Caucasian   colorectal cancer              PB        PCR--RFLP   197/212        rs11614913

  50   Roshni \[[@R70]\]         2014   Asian       oral cancer                    PB        PCR--RFLP   451/452        rs11614913

  51   Serena \[[@R71]\]         2011   Caucasian   Lung Cancer                    PB        RT-PCR      101/129        rs11614913, rs3746444

  52   Shen \[[@R72]\]           2015   Asian       ESCC                           PB        Hapmap      1400/2185      rs11614913, rs3746444

  53   Sushma \[[@R73]\]         2015   Caucasian   Oral Squamous\                 PB        PCR--RFLP   100/102        rs11614913, rs3746444
                                                    Cell Carcinoma                                                      

  54   Tian \[[@R74]\]           2009   Asian       lung cancer                    PB        PCR--RFLP   1058/1035      rs11614913, rs3746444

  55   Wang \[[@R75]\]           2014   Asian       HCC                            PB        PCR--RFLP   152/304        rs3746444

  56   Wu \[[@R76]\]             2013   Asian       gastric cancer                 PB        PCR--RFLP   200/211        rs3746444

  57   Yan \[[@R77]\]            2015   Asian       HCC                            PB        PCR--RFLP   274/328        rs11614913, rs3746444

  58   Z.Hu \[[@R78]\]           2008   Asian       breast cancer                  PB        PCR--RFLP   1009/1093      rs11614913, rs3746444

  59   Zhang \[[@R79]\]          2013   Asian       Acute lymphoblastic leukemia   PB        TaqMan      570/673        rs11614913

  60   Zhao \[[@R80]\]           2013   Asian       HCC                            PB        PCR--RFLP   235/281        rs11614913, rs3746444

  61   Zhou \[[@R81]\]           2014   Asian       HCC                            PB        PCR--RFLP   266/281        rs11614913, rs3746444

  62   Zhu \[[@R82]\]            2011   Asian       Colorectal Cancer              HB        RT-PCR      573/588        rs11614913
  ---------------------------------------------------------------------------------------------------------------------------------------------

HB, hospital based; PB, population based; HCC, hepatocellular carcinoma; ESCC, esophageal squamous cell carcinomar; PCR-RFLP, polymerase chain reaction--restriction fragment length.

polymorphism; PCR-CTPP, polymerase chain reaction with confronting two-pair primers; LDR, ligation detection reaction.

Statistical analysis {#s2_4}
--------------------

We first assessed the departure of frequencies of miRNA polymorphisms from expectation under Hardy-Weinberg equilibrium (HWE) for each study by using the goodness-of-fit test (chisquare or Fisher exact test) in controls. ORs corresponding to 95% CIs were calculated to access the strength of association between microRNA SNPs and cancer risks. Pooled ORs were obtained from combination of single study by heterozygote comparison (CT vs. CC for rs11614913; AG vs. AA for rs3746444), homozygote comparison (TT vs. CC for rs11614913; GG vs. AA for rs3746444), dominant model (TT + TC vs. CC for rs11614913; GG + AG vs. AA for rs3746444), recessive model (TT vs. CC + CT for rs11614913; GG vs. AG + AA for rs3746444) and allelic model (T vs. C for rs11614913; G vs. A for rs3746444) respectively. For each genetic comparison model, subgroup analysis according to ethnicity was investigated to estimate ethnic-specific ORs for Asian and Caucasian. Meanwhile stratified analyses by tumor type or control characteristics were also applied for each genetic comparison model.

Statistical heterogeneity between studies was checked by Cocharan's chi-square based *Q*-test \[[@R18]\] and quantified by I^2^. If the *P*-value for heterogeneity was \< 0.05, or if I^2^ was ≥ 50%, indicating substantial heterogeneity among studies, then a random-effect model using the DerSimonian and Laird method \[[@R31]\], which yielded wider CIs, was chosen to calculate the pooled OR; otherwise, a fixed-effect model using the Mantel-Haenszel method \[[@R19]\] was used. One-way sensitivity analyses were performed to assess the stability of the meta-analysis results \[[@R20]\]. Potential publication bias was estimated using Egger's linear regression test by visual inspection of the Funnel plot. All *P* value \< 0.05 was used as an indication of potential publication bias \[[@R21]\].

All statistical analyses were carried out with the review manager version 5.2 (Revman; The Cochrane Collaboration, Oxford, UK). All *P* values in the meta-analysis were two-sided, and *P* value less than 0.05 were considered significant.

RESULTS {#s3}
=======

Characteristics of the studies {#s3_1}
------------------------------

In total, 462 published studies were obtained though literature search, including the PubMed, EMBASE and CNKI database. Under conditions prescribed by the inclusion and exclusion criteria, 122 eligible studies (Figure [1](#F1){ref-type="fig"}) were retrieved, because they were no detailed evaluation. During data extraction, 62 eligible studies \[[@R22]--[@R83]\] were leaved, in which 56 and 37 studies were pooled for our meta-analysis, respectively (Figure [1](#F1){ref-type="fig"}). The characteristics of these selected studies are summarized in Table [1](#T1){ref-type="table"}. Among all the included studies, there were 13 studies (hepatocellular cancer), 12 studies (breast), 7 studies (gastric), 6 studies (colorectal), 4 studies (lung), and 20 studies (other cancer types), and one (breast/ovarian cancer). There were 48 studies of Asian population, 14 studies of Caucasian population. Generally speaking, 56 studies included in our meta-analysis with 21958 cases and 26436 controls, which were ultimately analyzed for miR-196a2C.T (rs11614913), 37 studies including 13759 cases and 17946 controls for miR-499 A.G(rs3746444) .

![Flow chart of the study selection process](oncotarget-08-114344-g001){#F1}

Quantitative synthesis {#s3_2}
----------------------

### miR-196a2C.T (rs11614913) {#s3_2_1}

For miR-196a2C.T rs11614913 polymorphism, our mate-analysis contain 56 studies (21958 cases and 26436 controls). We observed the T allele frequency via different ethnicities (Asian: 0.93, 95% CI = 0.91--0.96; Caucasian: 0.96, 95% CI = 0.90--1.02).

In the overall analysis, our mate-analysis results manifested a statistically significant association between the miR-196a2C.T rs11614913 and the reduced risks of cancers (OR = 0.93, 95% CI = 0.91--0.96, P~H~ \< 0.00001 for T vs. C), homozygote comparison (OR = 0.88, 95% CI = 0.83--0.93, P~H~ \< 0.00001 for TT vs. CC), dominant model (OR = 0.92, 95% CI = 0.89--0.96, P~H~ \< 0.00001 for TT + CT vs. CC) and recessive model (OR = 0.94, 95% CI = 0.90--0.98, P~H~ \< 0.00001 for TT vs. CC + CT ) ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

In subgroup analysis by cancer types, we found the significant associations between the miR-196a2C.T rs11614913 and colorectal cancer (OR = 1.21, 95% CI = 1.11--1.33, P~H~ \< 0.00001 for T vs. C; OR = 1.45, 95% CI = 1.21--1.74, P~H~ \< 0.00001 for TT vs.CC; OR = 1.25, 95% CI = 1.06--1.46, P~H~ \< 0.00001 for CT vs. CC; OR = 1.23, 95% CI = 1.05--1.43, P~H~ \< 0.00001 for TT + TC vs. CC; OR = 1.72, 95% CI = 1.50--1.98, P~H~ \< 0.00001 for TT vs. CC/TC); lung cancer (OR = 0.89, 95% CI = 0.82--0.97, P~H~ = 0.008 for T vs.C; OR = 0.79, 95% CI = 0.67--0.94, P~H~ = 0.26 for TT vs.CC; OR = 0.84, 95% CI = 0.74--0.96, P~H~ = 0.2 for TT vs. CC + TC); gastric cancer (OR = 0.77, 95% CI = 0.69--0.85, P~H~\< 0.00001 for T vs. C; OR = 0.54, 95% CI = 0.45--0.66, P~H~ \< 0.00001 for TT vs. CC; OR = 0.63, 95% CI = 0.52--0.75, P~H~ \< 0.00001 for CT vs. CC; OR = 0.66, 95% CI = 0.56--0.77, P~H~ \< 0.00001 for TT + CT vs. CC; OR = 0.76, 95% CI = 0.65--0.89, P~H~ \< 0.00001 for TT vs. CC + TC ). In addition, we also found the decreased risks in other cancer types (OR = 0.86, 95% CI = 0.82--0.90, P~H~ \< 0.00001 for T vs. C; OR = 0.90, 95% CI = 0.83--0.98, P~H~ \< 0.00001 for TT vs. CC; OR = 0.90, 95% CI = 0.84--0.97, P~H~ \< 0.00001 for TT + CT vs. CC; OR = 0.87, 95% CI = 0.81--0.93, P~H~ \< 0.00001 for TT vs. CC + TC ) (Figure [2](#F2){ref-type="fig"}). Subgroup analysis by the ethnicity revealed a significant association in the comparison of T vs.C (OR = 0.93, 95% CI = 0.91--0.96, P~H~ \< 0.00001), TT vs. CC (OR = 0.87, 95% CI = 0.82--0.92, P~H~ \< 0.00001), TT vs. CC + TC (OR = 0.91, 95% CI = 0.87--0.95, P~H~ \< 0.00001) in the Asian (Figure [3](#F3){ref-type="fig"}). Subgroup analysis by the source of control indicated a decreased risk in hospital based study, as showed in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

![Forest plot of cancer risk in different cancer types associated with miR-196a2 rs11614913 polymorphism for recessive model (TT + TC vs. CC)](oncotarget-08-114344-g002){#F2}

![Forest plot of cancer risk in different ethnicity associated with miR-196a2 rs11614913 polymorphism for recessive model (TT+TC vs. CC)](oncotarget-08-114344-g003){#F3}

miR-499 A.G rs3746444 {#s3_3}
---------------------

For miR-499A.G rs3746444, our mate-analysis included 37 studies (13759 cases and 17946 controls). our mate-analysis results are showed in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}. On the whole, we found that miR-499A.G rs3746444 was significantly associated with decreased risks of cancers under the G vs. A (OR = 1.14, 95% CI = 1.09--1.19, P~H~ \< 0.00001), GG vs. AA (OR = 1.20, 95% CI = 1.08--3.11, P~H~ \< 0.001), AG vs. AA (OR = 1.06, 95% CI = 1.01--1.11, P~H~ \< 0.00001 for), GG + GA vs. AA (OR = 1.16, 95% CI = 1.08--1.25, P~H~ = 0.07) and GG vs. AG + AA (OR = 1.20, 95% CI = 1.09--1.33, P~H~ \< 0.00001).

In stratified analysis according to cancer types, we investigated the significant associations with breast cancer were only maintained under the G vs. A (OR = 1.18, 95% CI = 1.09--1.27, P~H~ = 0.04), GG vs. AA (OR = 1.29, 95% CI = 1.08--1.56, P~H~ = 0.04), GG + GA vs. AA (OR = 1.29, 95% CI = 1.08--1.54, P~H\ =~ 0.02 ) and GG vs. AG + AA (OR = 1.18, 95% CI = 1.08--1.29, P~H~ = 0.18). However, no statistically significant association was found in colorectal, lung, liver or other types cancers (Figure [4](#F4){ref-type="fig"}). Subgroup analysis according to ethnicity, significant associations with increased risks of cancers were found in Asian population (OR = 1.13, 95% CI = 1.08--1.19, P~H~ \< 0.00001 for G vs. A; OR = 1.19, 95% CI = 1.06--1.34, P~H~ = 0.006 for GG vs. AA; OR = 1.17, 95% CI = 1.04--1.32, P~H\ =~ 0.01 for GG + GA vs. AA; OR = 1.12, 95% CI = 1.06--1.19, P~H~ \< 0.00001 for GG vs. AG + AA), and in Caucasian (OR = 1.16, 95% CI = 1.06--1.26, P~H~ \< 0.00001 for G vs. A; OR = 1.29, 95% CI = 1.07--1.57, P~H~ \< 0.00001 for GG + GA vs. AA; OR = 1.16, 95% CI = 1.04--1.29, P ~H~ = 0.001 for GG vs. AG + AA) (Figure [5](#F5){ref-type="fig"}). According to study design, we found significant association between population-based studies with elevated risks of cancer (OR = 1.15, 95% CI = 1.10--1.20, P~H~ \< 0.00001 for G vs. A; OR = 1.22, 95% CI = 1.09--1.36, P ~H~ \< 0.00001 for GG vs. AA; OR = 1.14, 95% CI = 1.08--1.20, P~H~ \< 0.00001 for GG + GA vs. AA; OR = 1.14, 95% CI = 1.08--1.20, P~H~ \< 0.00001 for GG vs. AG + AA), but the hospital-based studies was not observed a significant association summarized in [Supplementary Table 2](#SD3){ref-type="supplementary-material"}.

![Forest plot of cancer risk in different cancer types associated with miR-499 rs3746444 polymorphism for recessive model (GG+GA vs. AA)](oncotarget-08-114344-g004){#F4}

![Forest plot of cancer risk in different ethnicity associated with miR-499 rs3746444 polymorphism for recessive model (GG+GA vs. AA)](oncotarget-08-114344-g005){#F5}

Sensitivity analysis {#s3_4}
--------------------

In the sensitivity analysis, each study involved in our meta-analysis was deleted the influence of the individual data on the coalescent ORs. The results of sensitivity analysis showed no obvious effects in overall population.

Publication bias {#s3_5}
----------------

Begg's funnel plot and Egger's test were undertaken to evaluate the potential publication bias for this study. The shape of the Begg\'s funnel plots revealed no obvious asymmetry in all genotypes in overall population (Figures [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}). The Egger's test did not reveal publication bias (*P* \> 0.05).

![Funnel plot assessing evidence of publication bias (miR-196a2 rs11614913 (TT+TC vs. CC))](oncotarget-08-114344-g006){#F6}

![Funnel plot assessing evidence of publication bias (miR-499 rs3746444 (GG+GA vs. AA))](oncotarget-08-114344-g007){#F7}

DISCUSSION {#s4}
==========

The most common form of genetic sequence variation, SNPs are affecting miRNAs sequence coding, splicing and expression such as miRNA gene in human genome, which can affect the susceptibility of cancer including Asian and Caucasian \[[@R83]\]. It was detected in much previous research effort that the role of SNPs is located in miRNA sequence of miR-196a2 C.T (rs11614913) and miR-499 A.G (rs3746444) and influences on the progression of cancers \[[@R84]\]. Recently, several studies have investigated genetic variants of the miRNA SNPs in cancer susceptibility, but conclusions of those studies remain inconclusive. In this study, we conducted a meta-analysis to evaluated the association between the overall cancers susceptibility and the two polymorphisms in miRNA (miR-196a2 C.T rs11614913, miR-499 A.G rs3746444).

For miR-196a2 C.T rs11614913 polymorphism, although previous studies have revealed no association between cancer susceptibility and the expression of miR-196a2 rs11614913 \[[@R85]--[@R86]\]. Recently, the results of these meta-analysis studies have indicated a significant association between cancers susceptibility and miR-196a2 C.T rs11614913 \[[@R87]--[@R92]\]. The SNPs of miR-196a2 have caused increasing attention because they influence on the maturation progression and mutation of miRNA, and they play potential roles in tumor development and progression(cell proliferation, differentiation, apoptosis, migration and invasion). The predecessor found that the genetic sequence variation in miR-196a2 C.T rs11614913 is located in the 3′ passenger (3p) mature sequence of miR-196a2, and this functional polymorphism is reportedly associated with the susceptibility of multiple kind of tumors (lung cancer and breast cancer). However, there was lower survival rates in small cell lung cancer, gliomas, gastric cancer, gallbladder, head and neck, esophageal, and HCC . During this interim of more than one year, some relevant case-control studies have been published, while conclusions of the relevant studies remain incomprehensive and inconsistent. For example, Dai et al. \[[@R32]\] results revealed that the miR-499 A.G rs3746444 polymorphisms are related to increased risks of breast cancer, while the miR-196a2 C.T rs11614913 polymorphisms are connected with reduced risks of breast cancer. Wei's studies \[[@R93]\] suggested that the miR-196a2 C.T rs11614913 might not be connected with susceptibility to gastric cancer, while our study revealed that the miR-196a2 C.T rs11614913 decrease risks to cancer, especially colorectal and gastric cancer in Asians population, and that the miR-499A.G rs3746444 may increase risks of cancer. In subgroup analysis by cancer type, ours results indicate that significant association with risks of cancer was observed in colorectal, gastric and lung cancer. But we did not detect significant association in breast cancer. While Christensen et al. \[[@R94]\] showed the miR-196a2C.T rs11614913 may reduced incidence of breast cancer. In subgroup analysis according to ethnicity, we found the significant association with risks of cancer in Asian population, indicating a possible role of differences in genetic backgrounds between Asians and Caucasians.

As for miR-499A.G rs3746444 polymorphism, the pooled results studies revealed that the miR-499A.G rs3746444 was association with risks of cancer in multiple types of cancer \[[@R95]--[@R97]\]. Several studies showed that a large amount of miRNAs are abnormally expressed in various cancers, and Zhang et al. \[[@R98]\] found that approximately 50% miRNA genes are located in cancer-associated regions, so miRNAs possibly exert a signifcant effect on the tumorigenesis. It was reported that studies have shown that the miR-499 rs3746444 can regulate the expression of SOX genes. The over-expression of SOX6 could reverse the anti-apoptosis effects of miR-499 A.G rs3746444 \[[@R99]\]. The abnormal expression of SOX genes can activate Wnt/β-catenin signaling pathway, which is associated with tumorigenesis and progression, so miR-499 A.G rs3746444 may play a decisive role in the occurring of cancer by altering SOX genes' expression level. Moreover, the mate-analysis results from 37 studies revealed that the miR-499 rs3746444 G allele was revealed as a risk factor for cancers, in particular, for breast cancer or for in the Asian, which consistent with Hu's results \[[@R100]\]. Therefore, The results illustrated that cancer types and district classification could cause different effects between miR-499 A.G rs3746444 polymorphism and risks of cancer.

To our knowledge, the source of the heterogeneity, including miR-196a2 C.T rs11614913 and miR-499A.G rs3746444, were mainly results from different ethnicity, different cancer types, different source of controls, different selection of subjects and sample size. Therefore, we evaluated the source of heterogeneity by cancer types, ethnicity, different selection of subjects and sample size. Nevertheless, our meta-analysis indeed exist some boundedness. Firstly, lack of relevant published data from the collected studies of potential gene-to-gene and gene-to-environment interactions, which may adjust risks of cancer. Secondly, potential heterogeneity was detected in some comparison, because they are unavoidable. Finally, publication bias existed in studies.

In conclusion, our meta-analysis indicated that the miR-196a2 C.T rs11614913 is significantly associated with a decreased risk of cancers, especially in the subgroup of colorectal, lung and gastric cancer, or Asians. Contrary to the above, the miR-499A.G rs3746444 most likely contributes to increased susceptibility of cancer in overall population, especially in breast cancer. Furthermore, more well-designed researches with large sample size are still necessary to elucidate the correlation between polymorphisms and different kinds of cancers risk.
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